Literature DB >> 26970231

Report of the 19th follow-up survey of primary liver cancer in Japan.

Masatoshi Kudo1, Namiki Izumi1, Takafumi Ichida1, Yonson Ku1, Norihiro Kokudo1, Michiie Sakamoto1, Tadatoshi Takayama1, Osamu Nakashima1, Osamu Matsui1, Yutaka Matsuyama1.   

Abstract

The 19th Nationwide Follow-up Survey of Primary Liver Cancer in Japan comprised 20 850 primary liver cancer patients newly registered at 482 medical institutions over a period of 2 years (from 1 January 2006 to 31 December 2007). Of these, 94.7% had hepatocellular carcinoma (HCC) and 4.4% had intrahepatic cholangiocarcinoma (ICC). In addition, follow-up data were obtained regarding 34 752 patients who were registered in the previous survey. Epidemiological and clinicopathological factors, diagnosis, and treatment were examined in newly registered patients. Compared with the 18th follow-up survey, the present follow-up survey suggested an increase in the number of elderly and female patients, a reduction in the number of hepatitis B surface antigen- and anti-hepatitis C virus antibody-positive patients, and a reduction in tumor size at the time of clinical diagnosis. In terms of local ablation therapy, the number of patients receiving radiofrequency ablation therapy increased. The cumulative survival rates for newly registered patients between 1996 and 2007 were calculated for each histological type (HCC, ICC, and combined HCC and ICC) and stratified according to background factors and treatments. The cumulative survival rates of newly registered patients between 1978 and 2007 were calculated after dividing individuals into groups according to registration date (1978-1987, 1988-1997, and 1998-2007). The data obtained from this follow-up survey will contribute to the medical management of primary liver cancer and facilitate future research.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  combined hepatocellular and cholangiocarcinoma; cumulative survival rate; follow-up survey; hepatocellular carcinoma; intrahepatic cholangiocarcinoma

Year:  2016        PMID: 26970231     DOI: 10.1111/hepr.12697

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  45 in total

1.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

2.  Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.

Authors:  Kohei Nakachi; Masaru Konishi; Masafumi Ikeda; Kazuaki Shimada; Takuji Okusaka; Akio Saiura; Hiroshi Ishii; Masanori Sugiyama; Junji Furuse; Hirohiko Sakamoto; Tomotaka Shimamura; Takehiro Ohta
Journal:  Int J Clin Oncol       Date:  2018-04-28       Impact factor: 3.402

3.  Management of Hepatocellular Carcinoma in Japan as a World-Leading Model.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-12-13       Impact factor: 11.740

4.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

5.  Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma.

Authors:  Hiroya Iida; Masaki Kaibori; Shogo Tanaka; Shigekazu Takemura; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

6.  High dorsal resection for hepatocellular carcinoma: surgical plane and outcomes.

Authors:  Shintaro Yamazaki; Tadatoshi Takayama; Masaru Aoki; Nao Yoshida; Tokio Higaki
Journal:  Quant Imaging Med Surg       Date:  2021-08

7.  Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma.

Authors:  Taigo Hata; Tadashi Uwagawa; Katsuhiko Yanaga
Journal:  Liver Cancer       Date:  2019-03-01       Impact factor: 11.740

8.  Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

Authors:  MinKe He; QiJiong Li; RuHai Zou; JingXian Shen; WanQiang Fang; GuoSheng Tan; YuanMin Zhou; XiaoPing Wu; Li Xu; Wei Wei; Yong Le; ZhongGuo Zhou; Ming Zhao; Ying Guo; RongPing Guo; MinShan Chen; Ming Shi
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

9.  Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery.

Authors:  Tomoaki Yoh; Etsuro Hatano; Satoru Seo; Yukihiro Okuda; Hiroaki Fuji; Yoshinobu Ikeno; Kojiro Taura; Kentaro Yasuchika; Hideaki Okajima; Toshimi Kaido; Shinji Uemoto
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

10.  Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging.

Authors:  Sireesha Yedururi; Sumedha Chawla; Behrang Amini; Wei Wei; Usama I Salem; Ajaykumar C Morani; Wei-Lien Wang; Richard Gorlick; Valerae O Lewis; Najat C Daw
Journal:  Eur J Radiol       Date:  2018-05-21       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.